Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
35.87
+0.12 (0.34%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Crinetics Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 114.34 | 101.54 | 264.55 | 54.9 | 32.67 | 200.7 |
Short-Term Investments | 1,177 | 926.35 | 1,090 | 503.66 | 301.75 | 133.01 |
Cash & Short-Term Investments | 1,291 | 1,028 | 1,354 | 558.56 | 334.43 | 333.71 |
Cash Growth | 1.35% | -24.09% | 142.42% | 67.02% | 0.21% | 95.29% |
Accounts Receivable | 5.68 | 0.59 | - | - | - | - |
Inventory | 3.06 | 2.02 | - | - | - | - |
Other Current Assets | 22.36 | 17.84 | 21.32 | 15.6 | 10.76 | 11.01 |
Total Current Assets | 1,322 | 1,048 | 1,375 | 574.15 | 345.18 | 344.72 |
Net Property, Plant & Equipment | 53.29 | 54.79 | 55.58 | 57.43 | 4.99 | 4.72 |
Long-Term Investments | - | - | - | 0.47 | - | 1.01 |
Other Long-Term Assets | 25.62 | 23.13 | 3.63 | 3.3 | 2.01 | 0.57 |
Total Assets | 1,401 | 1,126 | 1,435 | 635.35 | 352.18 | 351.02 |
Accounts Payable | 37.49 | 41.77 | 21.47 | 23.2 | 15.35 | 8.47 |
Accrued Expenses | 25.79 | 35.58 | 28.89 | 14.52 | 9.08 | 6.59 |
Current Portion of Leases | 6.54 | 6.49 | 7.15 | 4.17 | 1.05 | - |
Unearned Revenue | 1.27 | 1.24 | 2.18 | 2.06 | 2.24 | - |
Other Current Liabilities | - | - | - | - | - | 0.94 |
Total Current Liabilities | 71.09 | 85.07 | 59.68 | 43.94 | 27.72 | 16 |
Long-Term Leases | 41.32 | 42.05 | 44.57 | 47.56 | 2.02 | 3.07 |
Other Long-Term Liabilities | 8.27 | 7.05 | 5.53 | 4.75 | 6.1 | 0 |
Total Long-Term Liabilities | 49.59 | 49.1 | 50.1 | 52.31 | 8.13 | 3.08 |
Total Liabilities | 120.68 | 134.17 | 109.79 | 96.25 | 35.85 | 19.07 |
Common Stock | 2,828 | 2,408 | 2,276 | 1,192 | 759.43 | 607.58 |
Treasury Stock | -1.03 | -0.11 | - | - | - | - |
Accumulated Other Comprehensive Income | -1.25 | 1.87 | 0.96 | 0.98 | -3.93 | -0.38 |
Retained Earnings | -1,545 | -1,417 | -952.11 | -653.7 | -439.17 | -275.26 |
Shareholders' Equity | 1,281 | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 |
Total Liabilities & Equity | 1,401 | 1,126 | 1,435 | 635.35 | 352.18 | 351.02 |
Total Debt | 47.86 | 48.54 | 51.72 | 51.73 | 3.08 | 3.07 |
Net Cash (Debt) | 1,243 | 979.35 | 1,302 | 506.83 | 331.35 | 330.63 |
Net Cash Growth | 26.97% | -24.80% | 156.96% | 52.96% | 0.22% | 98.14% |
Net Cash Per Share | 12.85 | 10.41 | 16.12 | 8.73 | 6.37 | 8.60 |
Book Value | 1,281 | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 |
Book Value Per Share | 13.23 | 10.55 | 16.40 | 9.28 | 6.09 | 8.64 |
Tangible Book Value | 1,281 | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 |
Tangible Book Value Per Share | 13.23 | 10.55 | 16.40 | 9.28 | 6.09 | 8.64 |